|
1
|
Jaffe N: Osteosarcoma: review of the past,
impact on the future. The American experience. Cancer Treat Res.
152:239–262. 2009.PubMed/NCBI
|
|
2
|
Hansen AR, Hughes BG, Paul S, et al:
Single institution retrospective review of perioperative
chemotherapy in adult and adolescent patients with operable
osteosarcoma. Asia Pac J Clin Oncol. Feb 20–2014.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haddox CL, Han G, Anijar L, et al:
Osteosarcoma in pediatric patients and young adults: a single
institution retrospective review of presentation, therapy and
outcome. Sarcoma. 2014:4025092014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gelderblom H, Jinks RC, Sydes M, et al:
European Osteosarcoma Intergroup: Survival after recurrent
osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI)
randomized controlled trials. Eur J Cancer. 47:895–902. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bacci G, Briccoli A, Longhi A, et al:
Treatment and outcome of recurrent osteosarcoma: experience at
Rizzoli in 235 patients initially treated with neoadjuvant
chemotherapy. Acta Oncol. 44:748–755. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014.PubMed/NCBI
|
|
7
|
Martins-Neves SR, Lopes AO, do Carmo A, et
al: Therapeutic implications of an enriched cancer stem-like cell
population in a human osteosarcoma cell line. BMC Cancer.
12:1392012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gibbs CP Jr, Levings PP and Ghivizzani SC:
Evidence for the osteosarcoma stem cell. Curr Orthop Pract.
22:322–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siclari VA and Qin L: Targeting the
osteosarcoma cancer stem cell. J Orthop Surg. 5:782010. View Article : Google Scholar
|
|
10
|
Yu L, Liu S, Zhang C, et al: Enrichment of
human osteosarcoma stem cells based on hTERT transcriptional
activity. Oncotarget. 4:2326–2338. 2013.PubMed/NCBI
|
|
11
|
Adhikari AS, Agarwal N, Wood BM, et al:
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells
associated with metastasis and drug resistance. Cancer Res.
70:4602–4612. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guruharsha KG, Kankel MW and
Artavanis-Tsakonas S: The Notch signalling system: recent insights
into the complexity of a conserved pathway. Nat Rev Genet.
13:654–666. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bianchi S, Dotti MT and Federico A:
Physiology and pathology of notch signalling system. J Cell
Physiol. 207:300–308. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fortini ME: Notch signaling: the core
pathway and its posttranslational regulation. Dev Cell. 16:633–647.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davis RL and Turner DL: Vertebrate hairy
and Enhancer of split related proteins: transcriptional repressors
regulating cellular differentiation and embryonic patterning.
Oncogene. 20:8342–8357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aranguren XL, Agirre X, Beerens M, et al:
Unraveling a novel transcription factor code determining the human
arterial-specific endothelial cell signature. Blood. 122:3982–3992.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin HY, Zhang HY, Wang X, Xu J and Ding Y:
Expression and clinical significance of Notch signaling genes in
colorectal cancer. Tumour Biol. 33:817–824. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ungerbӓck J, Elander N, Grünberg J,
Sigvardsson M and Söderkvist P: The Notch-2 gene is regulated by
Wnt signaling in cultured colorectal cancer cells. PLoS One.
6:e179572011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mysliwiec P and Boucher MJ: Targeting
Notch signaling in pancreatic cancer patients - rationale for new
therapy. Adv Med Sci. 54:136–142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Avila JL and Kissil JL: Notch signaling in
pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med.
19:320–327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maliekal TT, Bajaj J, Giri V, Subramanyam
D and Krishna S: The role of Notch signaling in human cervical
cancer: implications for solid tumors. Oncogene. 27:5110–5114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
McManus MM, Weiss KR and Hughes DP:
Understanding the role of notch in osteosarcoma. Adv Exp Med Biol.
804:67–92. 2014.PubMed/NCBI
|
|
23
|
Mu X, Isaac C, Greco N, Huard J and Weiss
K: Notch signaling is associated with ALDH activity and an
aggressive metastatic phenotype in murine osteosarcoma cells. Front
Oncol. 3:1432013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma Y, Ren Y, Han EQ, et al: Inhibition of
the Wnt-β-catenin and Notch signaling pathways sensitizes
osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun.
431:274–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hughes DP: How the NOTCH pathway
contributes to the ability of osteosarcoma cells to metastasize.
Cancer Treat Res. 152:479–496. 2009.PubMed/NCBI
|
|
26
|
Tanaka M, Setoguchi T, Hirotsu M, et al:
Inhibition of Notch pathway prevents osteosarcoma growth by cell
cycle regulation. Br J Cancer. 100:1957–1965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu L, Liu S, Guo W, et al: hTERT promoter
activity identifies osteosarcoma cells with increased EMT
characteristics. Oncol Lett. 7:239–244. 2014.PubMed/NCBI
|
|
28
|
Thorn CF, Oshiro C, Marsh S, et al:
Doxorubicin pathways: pharmacodynamics and adverse effects.
Pharmacogenet Genomics. 21:440–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu YP, Yang CJ, Huang MS, et al:
Cisplatin selects for multidrug-resistant CD133+ cells in lung
adenocarcinoma by activating Notch signaling. Cancer Res.
73:406–416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu J and Mao Z, Huang J, Xie S, Liu T and
Mao Z: Blocking the NOTCH pathway can inhibit the growth of
CD133-positive A549 cells and sensitize to chemotherapy. Biochem
Biophys Res Commun. 444:670–675. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang M, Ma X, Wang J, Wang L and Wang Y:
Pretreatment with the γ-secretase inhibitor DAPT sensitizes
drug-resistant ovarian cancer cells to cisplatin by downregulation
of Notch signaling. Int J Oncol. 44:1401–1409. 2014.PubMed/NCBI
|
|
32
|
Zhou JX, Han JB, Chen SM, et al:
γ-secretase inhibition combined with cisplatin enhances apoptosis
of nasopharyngeal carcinoma cells. Exp Ther Med. 3:357–361.
2012.PubMed/NCBI
|
|
33
|
Zang S, Chen F, Dai J, et al:
RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition
and enhanced chemosensitivity in human breast cancer. Oncol Rep.
23:893–899. 2010.PubMed/NCBI
|
|
34
|
Nefedova Y, Sullivan DM, Bolick SC, Dalton
WS and Gabrilovich DI: Inhibition of Notch signaling induces
apoptosis of myeloma cells and enhances sensitivity to
chemotherapy. Blood. 111:2220–2229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang ZP, Sun YL, Fu L, Gu F, Zhang L and
Hao XS: Correlation of Notch1 expression and activation to
cisplatin-sensitivity of head and neck squamous cell carcinoma. Ai
Zheng. 28:100–103. 2009.PubMed/NCBI
|
